Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review - Scorecard - MDSpire

Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review

  • By

  • Jingge Miao

  • Nianqiu Liu

  • Fuhong Gong

  • Jiayi Chen

  • Chenxi Wang

  • Mengping Lin

  • Na Li

  • Yilin Chen

  • Fei Ge

  • Wenlin Chen

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Concurrent Invasive Breast Carcinoma and Metastatic High-Grade Serous Ovarian Carcinoma: A Case Study and Review of Existing Literature

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPremenopausal women with concurrent breast and ovarian carcinoma.
Care Setting

Key Highlights

  • additional_highlight

Guideline-Based Recommendations

Diagnosis

  • Use morphology and immunohistochemistry (e.g., WT1, PAX8, CA125) to distinguish between primary and metastatic lesions.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Utilization of PARP inhibitors for maintenance therapy due to BRCA mutation, which guided treatment decisions.

        Clinical Best Practices

        • additional_practice

        Related Resources & Content

        Original Source(s)

        Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review

        • by Jingge Miao, Nianqiu Liu, Fuhong Gong, Jiayi Chen, Chenxi Wang, Mengping Lin, Na Li, Yilin Chen, Fei Ge, Wenlin Chen

        • June 17, 2026

        Related Content

        Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications

        Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside—a narrative review

        Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance